The $8.5 million difference

Less than two years after telling start-up GeneSys Therapeutics Corp. that it should seek a merger partner because of a glut of gene therapy companies, Kleiner Perkins Caufield & Byers is backing GeneMedicine Inc.

The reason: it's a different kind of gene therapy company, one focused on in vivo drugs instead of ex vivo services using retroviral vectors.